ArticleJournal of neuro-oncology2026
High-dose chemotherapy and craniospinal irradiation-sparing approach for WNT medulloblastoma of early childhood.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant chemotherapy and craniospinal irradiation led to excellent survival in older children (≥ 3 years) with WNT medulloblastoma, allowing for ongoing careful treatment de-escalation. However, treatment with standard dose chemotherapy alone or in combination with involved field radiotherapy to the tumor bed only had high rates of distant treatment failure. In younger children, WNT medulloblastomas are extremely rare and the survival following high-dose chemotherapy (HDC) and radiation-sparing strategies has not been reported. PATIENTS AND
methodsThrough international collaboration, we assembled a cohort of young children with WNT medulloblastoma treated with HDC and craniospinal irradiation avoidance to describe their survival and neurocognitive and ototoxicity profile.
resultsFive patients, diagnosed at median age of 7.0 years (range 2.7–7.5) underwent HDC and autologous stem cell transplantation. None of them received adjuvant radiotherapy. All patients were alive beyond four years from diagnosis. Evaluated patients had neurocognitive abilities reported within low average to average range.
conclusionIn this cohort, the survival of young children with WNT MB treated with HDC alone was excellent. The rare possibility of a molecular diagnosis of WNT MB in early childhood should not be viewed as an exclusion criterion to enroll on infant brain tumor strategies relying on HDC consolidation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
41553441What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.